Deucravacitinib in Japanese patients with plaque, generalized pustular, or erythrodermic psoriasis: Patient-reported outcomes in the POETYK PSO-4 study

By sjmartinez • December 7, 2024

Tada Y, Armstrong AW, Imafuku S, Okubo Y, Morita A, Zhong Y, Zhuo J, Becker B, Napoli A, Banerjee S, Ohtsuki M. Deucravacitinib in Japanese patients with plaque, generalized pustular, or erythrodermic psoriasis: Patient-reported outcomes in the POETYK PSO-4 study. J Dermatol. 2024 Dec 6. doi: 10.1111/1346-8138.17570. Epub ahead of print. PMID: 39641509.

Tags: Clinical Trial, Dermatology, patient‐reported outcome measures, psoriasis, Publications, Quality of Life, Treatment outcome

Exacerbation of bullous systemic lupus erythematosus with erythema gyratum repens-like pattern following dupilumab

Santiago Mangual KP, Truong A, Mo J, Liu J, Khaligi MA, Haussmann A, Razmjou AA, Holland V, Cheng K. Exacerbation of bullous systemic lupus erythematosus[...]

Chronic companions: An updated national cross-sectional study of metabolic syndrome comorbidities in outpatient visits for hidradenitis suppurativa

Ma EJ, Roberts AM, Chou P, Katz A, Jeong CY, Nong Y, Ochoa MT, Armstrong AW. Chronic companions: An updated national cross-sectional study of metabolic[...]

Anchored Matching-Adjusted Indirect Comparison of the Long-Term Maintenance of Efficacy of Tralokinumab and Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis

Augustin M, Armstrong A, Issa NT, Petersen AS, von Eyben R, Festini T, Torres T. Anchored Matching-Adjusted Indirect Comparison of the Long-Term Maintenance of Efficacy[...]